Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ALLR

ALLR - Allarity Therapeutics, Inc. Stock Price, Fair Value and News

0.40USD0.00 (0.00%)Delayed as of 22 Feb 2024, 10:00 am ET
Watchlist

Market Summary

USD0.400.00
Delayedas of 22 Feb 2024, 10:00 am
0.00%

ALLR Stock Price

View Fullscreen

ALLR RSI Chart

ALLR Valuation

Market Cap

1.8M

Price/Earnings (Trailing)

-0.14

Price/Free Cashflow

-0.13

ALLR Price/Earnings (Trailing)

ALLR Profitability

Return on Equity

-14.73%

Return on Assets

-93.82%

Free Cashflow Yield

-741.4%

ALLR Fundamentals

ALLR Earnings

Earnings (TTM)

-13.0M

Earnings Growth (Yr)

11.71%

Earnings Growth (Qtr)

-86.85%

Breaking Down ALLR Revenue

52 Week Range

0.41
(Low)(High)

Last 7 days

-7.0%

Last 30 days

-18.4%

Last 90 days

-23.1%

How does ALLR drawdown profile look like?

ALLR Financial Health

Current Ratio

0.28

Debt/Equity

0.01

Debt/Cashflow

-16.65

ALLR Investor Care

Buy Backs (1Y)

55.57%

Diluted EPS (TTM)

1.8K

Which funds bought or sold ALLR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 14, 2024
CITADEL ADVISORS LLC
sold off
-100
-19,583
-
-%
Feb 14, 2024
TWO SIGMA SECURITIES, LLC
added
198
11,292
20,694
-%
Feb 14, 2024
SABBY MANAGEMENT, LLC
sold off
-100
-268,472,000
-
-%
Feb 13, 2024
Tower Research Capital LLC (TRC)
reduced
-0.97
-1,125
3,051
-%
Feb 13, 2024
ARMISTICE CAPITAL, LLC
sold off
-100
-194,967
-
-%
Feb 09, 2024
WELLS FARGO & COMPANY/MN
added
433
14.00
18.00
-%
Feb 07, 2024
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
sold off
-
-
-
-%
Feb 07, 2024
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
sold off
-
-
-
-%
Nov 15, 2023
Virtu Financial LLC
new
-
19,000
19,000
-%

1–9 of 9

Are Funds Buying or Selling ALLR?

Are funds buying ALLR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ALLR
No. of Funds

Unveiling Allarity Therapeutics, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 12, 2024
3i, lp
9.9%
653,377
SC 13G/A

Recent SEC filings of Allarity Therapeutics, Inc.

View All Filings
Date Filed Form Type Document
Feb 14, 2024
8-K
Current Report
Feb 12, 2024
SC 13G/A
Major Ownership Report
Feb 02, 2024
D
D
Feb 01, 2024
8-K
Current Report
Jan 26, 2024
PRE 14A
PRE 14A
Jan 25, 2024
8-K
Current Report
Jan 19, 2024
8-K
Current Report
Dec 15, 2023
S-1/A
Initial Public Offering
Dec 11, 2023
8-K
Current Report
Dec 06, 2023
8-K
Current Report

Allarity Therapeutics, Inc. News

Latest updates
TipRanks14 Feb 202402:14 pm

Allarity Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Assets3.3%13,87513,42612,70214,54418,13423,23131,29049,63336,98738,78036,09233,40332,95432,50532,05631,607
  Current Assets19.0%4,3873,6862,9664,9686,06110,11917,21121,4047,6358,497-1,715---3,343
    Cash Equivalents298.6%1,3993512952,0293,9467,67714,54419,5555,5846,59810529830.00391-1,524
  Net PPE11.5%29.0026.0025.0021.005.005.006.008.009.0010.00-21.00---37.00
Liabilities21.9%17,25414,14913,04112,65414,63113,14914,41630,8497,3269,9609,4628,9649,3999,83410,26910,704
  Current Liabilities24.3%15,74412,66811,58811,22212,95511,46212,71120,7193,8384,335-5,533---4,719
  Long Term Debt------812-785773--737----
    LT Debt, Current---2,6872,644-------1,327----
Shareholder's Equity7.0%88,36682,58883,43783,1581,4477,96614,73218,15229,66128,82323,46824,43922,73921,36121,00620,035
  Retained Earnings-5.0%-92,729-88,282-85,902-82,550-79,712-74,675-69,572-66,492-49,676-45,090--39,844----32,374
  Additional Paid-In Capital7.0%88,36682,58883,43783,15883,02983,86884,23385,24378,94867,933-62,482---50,623
Shares Outstanding-4,186-1,188-10,2609,2838,8428,0967,7534,7774,5334,252-132,666-121,336
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Cashflow From Operations-115.4%-5,376-2,496-3,201-2,446-4,408-4,208-5,755-4,319-3,734-4,266-2,567-2,439-905---
  Share Based Compensation-31.1%124180-121340406-59.001,0655,163577433195-12.00236---
Cashflow From Investing-----18.00--8095.00--------
Cashflow From Financing125.1%6,4502,8651,1581,000---18,4372,34610,7102,3252,7001,314---

ALLR Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:    
Research and development$ 1,948$ 3,004$ 4,480$ 5,989
Impairment of intangible assets14,007
General and administrative2,4781,5587,7707,717
Total operating expenses4,4264,56212,25027,713
Loss from operations(4,426)(4,562)(12,250)(27,713)
Other income (expenses)    
Income from sale of IP1,780
Interest income12141919
Interest expense(34)(35)(268)(107)
Loss on investment(45)(115)
Foreign exchange losses(156)(406)(87)(944)
Fair value of New September Warrants(4,189)(4,189)
Fair value of modification to April & July 2023 Warrants(591)(591)
Change in fair value adjustment of derivative and warrant liabilities4,93727,18713,442
Penalty on Series A Preferred Stock liability(800)
Net other income (loss)(21)(470)2,07113,275
Net loss for the period before tax expense(4,447)(5,032)(10,179)(14,438)
Income tax benefit (expense)(5)1,218
Net loss(4,447)(5,037)(10,179)(13,220)
Cash payable on converted Series A Preferred Stock(1,646)(1,646)
Deemed dividends on Series A Preferred Stock(1,105)(8,392)(1,572)
Deemed dividend on Series C Preferred Stock(123)
Cash paid on converted Series A Preferred Stock(1,511)
Net loss attributable to common stockholders$ (5,552)$ (6,683)$ (18,694)$ (17,949)
Basic net loss per common stock (in Dollars per share)$ (2.24)$ (934.29)$ (19.38)$ (2,733.21)
Weighted-average number of common stock outstanding, Basic (in Shares)2,474,7247,153964,3756,567
Other comprehensive loss, net of tax:    
Net loss$ (4,447)$ (5,037)$ (10,179)$ (13,220)
Change in cumulative translation adjustment(92)(643)(37)(1,271)
Comprehensive loss attributable to common stockholders$ (4,539)$ (5,680)$ (10,216)$ (14,491)

ALLR Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash$ 1,399$ 2,029
Other current assets1,0291,559
Prepaid expenses396591
Tax credit receivable1,563789
Total current assets4,3874,968
Non-current assets:  
Property, plant and equipment, net2921
Operating lease right of use assets6
Intangible assets9,4599,549
Total assets13,87514,544
Current liabilities:  
Accounts payable6,3476,251
Accrued liabilities1,4851,904
Warrant liability3,938
Derivative warrant liability3,946374
Income taxes payable2841
Convertible debt and accrued interest, net of debt discount2,644
Operating lease liabilities, current8
Total current liabilities15,74411,222
Non-current liabilities:  
Convertible promissory note and accrued interest, net of debt discount1,1671,083
Deferred tax343349
Total liabilities17,25412,654
Commitments and contingencies (Note 16)
Redeemable preferred stock (500,000 shares authorized)  
Total redeemable preferred stock2,003
Stockholders’ (deficit) equity  
Series A Preferred stock $0.0001 par value (20,000 shares designated) shares issued and outstanding at September 30, 2023 and December 31, 2022 were 1,417 and 13,586 respectively (liquidation preference of $17.54 at September 30, 2023)1,742
Common Stock, $0.0001 par value (750,000,000 and 30,000,000 shares authorized, at September 30, 2023 and December 31, 2022, respectively); shares issued and outstanding at September 30, 2023 and December 31, 2022 were 4,185,263 and 454,225, respectively
Additional paid-in capital88,36683,158
Accumulated other comprehensive loss(758)(721)
Accumulated deficit(92,729)(82,550)
Total stockholders’ deficit(3,379)(113)
Total liabilities, preferred stock and stockholders’ (deficit) equity13,87514,544
Series A Preferred Stock  
Redeemable preferred stock (500,000 shares authorized)  
Convertible Preferred stock value2,001
Series B Preferred Stock  
Redeemable preferred stock (500,000 shares authorized)  
Convertible Preferred stock value2
Series C Convertible Preferred Stock  
Redeemable preferred stock (500,000 shares authorized)  
Convertible Preferred stock value
ALLR
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
0
 CEO
 WEBSITEwww.allarity.com

Allarity Therapeutics, Inc. Frequently Asked Questions


What is the ticker symbol for Allarity Therapeutics, Inc.? What does ALLR stand for in stocks?

ALLR is the stock ticker symbol of Allarity Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Allarity Therapeutics, Inc. (ALLR)?

As of Wed Feb 21 2024, market cap of Allarity Therapeutics, Inc. is 1.82 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALLR stock?

You can check ALLR's fair value in chart for subscribers.

What is the fair value of ALLR stock?

You can check ALLR's fair value in chart for subscribers. The fair value of Allarity Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Allarity Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALLR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Allarity Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether ALLR is over valued or under valued. Whether Allarity Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Allarity Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALLR.